Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Non-interventional Post-authorization Effectiveness Study to Assess Long-term Outcomes of Nintedanib Treatment in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

NCT07080125 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07080125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07080125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Non-interventional Post-authorization Effectiveness Study to Assess Long-term Outcomes of Nintedanib Treatment in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Active, not recruiting
Start date
June 17, 2025
Completion date
December 31, 2033
Enrollment
2,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

interstitial lung diseases, systemic sclerosis associated interstitial lung disease